Nan Li is a venture capital investor at Dimension who built his career at the intersection of computer science and life sciences, positioning himself early around the convergence of computation and biology before it became mainstream. He focuses on partnering with technical founding teams developing platforms that generate proprietary biological datasets rather than generic AI models, emphasizing that differentiated data and infrastructure are the true advantages in computational drug discovery.

• Focused heavily on the intersection of artificial intelligence and life sciences, viewing this combination as a fundamental platform shift. The core belief is that machine learning models and dedicated operating systems will revolutionize biological research and drug discovery. A prime example is the repeated praise for Chai Discovery, a portfolio company using generative design to create full-length antibodies with atom-level precision.
• Deeply interested in next-generation therapeutics and regenerative medicine platforms that translate complex science into tangible patient treatments. The emphasis is on building comprehensive technological stacks that handle everything from cell engineering to robotic manufacturing. For instance, the investor highlighted Aspect Biosystems as a generational company for combining computer vision, biomaterials, and tissue engineering to advance tissue implantation.
• Emphasizes execution speed and highly concentrated talent when evaluating startup teams. The messaging consistently points out how quickly portfolio companies progress from early technical breakthroughs to massive commercial partnerships or product launches. This was evident when highlighting how the founders of Tamarind Bio rapidly secured landmark model access deals and dedicated supercomputers within a single year.
• Actively deploying large-scale capital into all stages of companies bridging software and biology. The firm recently launched a five hundred million dollar second fund to double down on specialized areas like research software, data infrastructure, and molecular devices. Founders should know there is an appetite for both early-stage tools aimed at reducing animal testing, like Axiom, and massive late-stage therapeutic rounds, like the oversubscribed financing for Odyssey Therapeutics.